Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report

INTRODUCTION: In the past, no effective systemic therapy has existed for patients with advanced hepatocellular carcinoma. Sorafenib, an oral multikinase inhibitor, has recently been shown to improve overall survival in patients with advanced hepatocellular carcinoma in two randomized, double-blinded...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Okuwaki, Yusuke, Nakazawa, Takahide, Hidaka, Hisashi, Shibuya, Akitaka, Koizumi, Wasaburo
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2012
Teme:
Case Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3275456/
https://ncbi.nlm.nih.gov/pubmed/22280970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1752-1947-6-38
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items